Poolbeg Pharma PLC (LSE:POLB)has announced plans to raise approximately £4.1 million through a combination of share placing and subscriptions, aiming to accelerate the development of two of its key experimental drug programmes. The funding is expected to support upcoming clinical trials focused on cancer …
Arecor Therapeutics plc (AIM: AREC)has announced a new collaboration with US-based Skye Bioscience (Nasdaq: SKYE) to develop a higher concentration formulation of nimacimab, a monoclonal antibody currently under investigation for the treatment of obesity and related metabolic conditions.
Genflow Biosciences PLC (LSE:GENF, OTCQB:GENFF) has announced progress in securing intellectual property protection for its core gene therapy technology in Japan, with the country’s patent office advancing a key application to the national examination stage.
In a strategic move to bolster its liver disease portfolio, GSK plc (LSE:GSK) has announced the acquisition of efimosfermin alfa, a promising investigational treatment for steatotic liver disease (SLD), from Boston Pharmaceuticals. The deal, valued at $2 billion, includes an upfront payment of $1.2 …
GSK (LSE:GSK)has made a positive start to 2025, posting growth in sales, profits, and earnings, with performance underpinned by its thriving Specialty Medicines segment and strategic investments in pipeline advancement.
Smith+Nephew plc (LSE:SN, NYSE:SNN)reported growth for the first quarter ended 29 March 2025, driven by operational improvements and new product launches, despite external challenges including continued headwinds from China and one fewer trading day compared to the prior year.
Shares in AstraZeneca PLC (LSE:AZN) dropped by 4% in early London trading following the release of its first-quarter 2025 results, as a slight miss on revenue forecasts overshadowed stronger-than-expected earnings and a standout performance in its oncology segment.
Reckitt Benckiser Group PLC reported a resilient performance in the first quarter of 2025, with like-for-like (LFL) net revenue for Core Reckitt increasing by 3.1%. This growth was primarily fuelled by a performance from its Powerbrands, notably Germ Protection (up 7.5%) and Intimate Wellness …
GSK plc (LSE/NYSE: GSK) has received a significant step forward in the U.S. vaccination landscape, as the CDC's Advisory Committee on Immunization Practices (ACIP) voted to recommend the use of Penmenvy, a combined meningococcal vaccine. Penmenvy, which protects against meningococcal groups A, B, C, …
Assura plc (LSE:AGR), a prominent healthcare infrastructure investor and developer in the UK and Ireland, has agreed to a recommended cash acquisition by Sana Bidco Limited, in a deal that values the company at approximately £1.61 billion on a fully diluted basis.